ovarian cancer

News
ImmunoGen

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

Digital
Ovarian cancer

Ovarian cancer, Olivia, and the OCC – part one

Following the European Society of Gynaecological Oncology (ESGO) 2022 congress, pharmaphorum spoke with experts from among the Ovarian Cancer Commitment (OCC) founding partners – ESGO, the